Drug Description
Each tablet contains 800 mg sevelamer carbonate.
Presentation
Filmcoated tablet (tablet).The white to offwhite tablets are imprinted with “RENVELA 800” on one side.
Indications
Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.
Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Adult Dosage
Posology
